Microchip Technology Incorporated

Microchip Technology screens as undervalued on a price-to-sales basis, with the current 9.8x P/S level sitting at a discount to its modelled fair sales multiple. The median Wall Street price target of $118.50 implies 33.8% upside from current levels, supported by 19 Buy ratings and zero Sell ratings among analysts.

A DCF intrinsic value analysis suggests Microchip Technology is overvalued by approximately 26.1%, meaning current prices may already exceed what projected future cash flows can justify. The fundamental question remains whether the company can convert its product pipeline into sustained, cash-generative growth to support any premium multiple.

Microchip Technology posted Q4 FY2026 revenue of $1.31 billion, up 35% year-over-year and beating the high end of guidance. Forecasts project earnings and revenue growing at 36% and 13.3% per annum respectively, with EPS growth of 36.6% annually, pointing to a robust and durable recovery trajectory.

Despite the strong recovery numbers, a price projection to $138 by March 2029 implies only ~12% annualized returns, using a conservative exit P/E of 25.6x — well below MCHP's one-year average of 35.2x. This suggests the market may already be pricing in much of the recovery, leaving limited additional upside.

JPMorgan strategist Mislav Matejka views recent semiconductor weakness as a buying opportunity, maintaining that the semiconductor upcycle is not peaking and that meaningful new supply is unlikely before 2028. New Microchip Technology products in mixed-signal microcontrollers and aerospace timing devices provide additional institutional catalysts beyond the AI trade.

Technical indicators for MCHP present a range-bound outlook with downside risk dominating, with a 68% likelihood of a downward price movement in the near term. The MACD signals a strong sell, the RSI hints at negative sentiment, and the Stochastic RSI indicates overbought conditions, suggesting near-term price fatigue.